Related Experiment Videos
Renal experience with Visipaque
1Department of Radiology, Rikshospitalet, University of Oslo, Norway.
European Radiology
|January 1, 1996
Summary
The new dimeric non-ionic contrast medium Visipaque showed good renal tolerance in healthy volunteers and patients with severe renal failure. Visipaque caused minimal renal effects, comparable to monomeric contrast media in specific patient groups.
Area of Science:
- Nephrology
- Radiology
- Pharmacology
Background:
- Contrast media (CM) are essential for medical imaging but can affect renal function.
- Dimeric non-ionic contrast media represent a newer class of agents with potentially improved safety profiles.
Purpose of the Study:
- To investigate the renal effects of Visipaque, a dimeric non-ionic contrast medium.
- To compare the renal safety of Visipaque with a monomeric contrast medium (Omnipaque) in healthy volunteers and patients with severe renal failure.
Main Methods:
- Intravenous injections of Visipaque and Omnipaque were administered to healthy volunteers and predialytic patients.
- Glomerular filtration rate (GFR) and tubular function were assessed.
- Excretion of tubular enzymes and iodine retention were measured.
Main Results:
- Visipaque caused no GFR changes in healthy volunteers and fewer tubular function changes than monomeric CM.
- Both Visipaque and Omnipaque caused small, transient GFR changes in predialytic patients.
- Delayed excretion of both CM was observed in predialytic patients, with no significant differences in tubular enzymes or glomerular parameters between the two.
- Higher iodine retention was observed with Visipaque, but this did not correlate with renal function changes.
Conclusions:
- Visipaque is well-tolerated in individuals with normal renal function.
- Visipaque demonstrates comparable or improved renal safety compared to monomeric contrast media in patients with severe renal failure.